Biom’up appoints George Makhoul as Chief Commercial Officer (USA)

Saint-Priest, France, January 31, 2019 – 8h00 (CET) – Biom’up (the « Company »), specializing in surgical hemostasis, today announced the appointment of George Makhoul as Chief Commercial Officer with responsibility for the United States, effective today.

Mr. Makhoul has a track record in commercializing medical products to hospitals and surgeons combined with a strong experience of the US hemostasis market. He will oversee all Biom’up sales and marketing activities in the US and work to strengthen the presence of the Company in this strategic market as the launch of its flagship product HEMOBLAST™ Bellows, a hemostatic product to control bleeding in a broad range of both traditional and laparoscopic surgical procedures, continues to gain market traction.

He joins a team of veteran sales and marketing executives overseeing a nationwide network of more than 200 representatives. He will report directly to the Group CEO, Mr. Etienne Binant.

Etienne Binant, Chief Executive Officer of Biom’up, declared: « The entire Biom’up team joins me to welcome George Makhoul as a new senior executive member. George is a proven commercial leader and a strategic thinker with cross-divisional experience in both sales and marketing roles in medical device and pharmaceutical companies. George joins us at an opportune time to accelerate the emerging commercial success of HEMOBLAST Bellows as the hemostatic product of choice for surgeons in the U.S. market. We all very much look forward to working with him. »

George Makhoul said:I am enthusiastic about joining Biom’up. The commitment to excellence from everyone in the organization positions us for disruptive and exponential growth in the hemostasis market.

George Makhoul has over 16 years of sales, marketing, and business development leadership experience in both the medical device and pharmaceutical industries, specifically in hemostasis as well as over 13 years of targeted focus in Biosurgery, Orthopedics, and Biologics. He has led teams on both a large and small scale ranging from $10M – $1.8B in annual revenues.

Prior to joining Biom’up, Mr. Makhoul spent eight years at Stryker in multiple senior leadership positions. While at Stryker, Mr. Makhoul successfully led the sales and marketing functions of two separate new divisions within Stryker’s Orthobiologics business unit, including leading teams that developed products from conception to commercialization. Other organizations he has served prior to Stryker are Wyeth (now Pfizer), Genzyme, and Precision Therapeutics.

George Makhoul holds a degree in Business Management from Moravian College.

Download the full press release

ALL PRESS RELEASE

Caution: Federal law restricts this device to sale on or by the order of a physician. The trademark of HEMOBLAST™ Bellows and SPOT GRADE™ are the property of Biom’up. The trademarks of the products listed herein are trademarks of their respective manufacturer. Please refer to the Instructions for Use accompanying each device for further information. The presentation contains pictures owned by third party and remains their property.
E-MR-318-V1
HEMOBLAST™ Bellows Hemostatic Agent [instructions for use: E-MR-217-V6]